After search, choose a molecule or a kind of categories listed in the left to narrow down your filter. If you have any problems, please contact us!
Text Size:AAA

TRAIL R4 / CD264 / TNFRSF10D Antibody, Mouse MAb

DatasheetReviewsRelated ProductsProtocols
Human TRAILR4 Antibody Product Information
Immunogen:Recombinant Human TRAIL R4 / CD264 / TNFRSF10D Protein (Catalog#10413-H08H)
Clone ID:2F8B1
Ig Type:Mouse IgG1
Formulation:0.2 μm filtered solution in PBS with 5% trehalose
Preparation:This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human TRAIL R4 / CD264 / TNFRSF10D (rh TRAIL R4 / CD264 / TNFRSF10D; Catalog#10413-H08H; NP_003831.2; Met 1-His 211). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
Human TRAILR4 Antibody Usage Guide
Specificity:Human TRAIL R4 / CD264 / TNFRSF10D
No cross-reactivity in ELISA with
Human TNFa
Human cell lysate (293 cell line)
Application:ELISA, IHC-P

ELISA: 0.5-1 μg/mL

This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human TNFRSF10D. The detection limit for Human TNFRSF10D is approximately 0.078 ng/well.

IHC-P: 5-20 μg/mL

Storage:This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Human TRAILR4 Antibody IHC Application Image
TRAIL R4 / CD264 / TNFRSF10D Antibody, Mouse MAb
[Click to enlarge image]
Immunochemical staining of human TNFRSF10D in human kidney with mouse monoclonal antibody (10 µg/mL, formalin-fixed paraffin embedded sections).
TRAIL R4 / CD264 / TNFRSF10D Antibody, Mouse MAb
[Click to enlarge image]
Immunochemical staining of human TNFRSF10D in human liver with mouse monoclonal antibody (10 µg/mL, formalin-fixed paraffin embedded sections).
Other TRAILR4 Antibody Products
TRAIL R4/CD264/TNFRSF10D Background

Tumor necrosis factor receptor superfamily member 10D (TNFRSF10D), also known as TNF-related apoptosis-inducing ligand receptor 4 (TRAIL R4), CD264, and Decoy receptor 2, is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain, a transmembrane domain, and a truncated cytoplamic death domain. This receptor does not induce apoptosis, and has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. TRAIL R4/CD264/TNFRSF10D is widely expressed, in particular in fetal kidney, lung and liver, and in adult testis and liver. TRAIL R4/CD264/TNFRSF10D is also expressed in peripheral blood leukocytes, colon and small intestine, ovary, prostate, thymus, spleen, pancreas, kidney, lung, placenta and heart. The signaling capacity of TRAIL R4 is similar to that of TRAIL R1 and TRAIL R2 with respect to NF-κB activation, but differs in its inability to induce apoptosis. TRAIL R4 retains a C-terminal element containing one third of a consensus death domain motif. Transient overexpression of TRAIL R4 in cells normally sensitive to TRAIL-mediated killing confers complete protection, suggesting that one function of TRAIL R4 may be inhibition of TRAIL cytotoxicity.

Human TRAIL R4/CD264/TNFRSF10D References
  • Degli-Esposti MA, et al. (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7(6): 813-20.
  • Meng RD, et al. (2000) The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther. 1(2): 130-44.
  • Bouralexis S, et al. (2003) Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer. 89(1): 206-14.
  • Product nameProduct name
    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.